Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1

Interventions

Cyclophosphamide 12Biopsy 10Specimen Handling 9Whole-Body Irradiation 7Magnetic Resonance Spectroscopy 7pembrolizumab 6Peripheral Blood Stem Cell Transplantation 6Melphalan 6Etoposide 6fludarabine 5duvelisib 5Brentuximab Vedotin 5ruxolitinib 4fludarabine phosphate 4Vincristine 4Prednisone 4Doxorubicin 4Cytarabine 410-propargyl-10-deazaaminopterin 4romidepsin 3X-Rays 3Mycophenolic Acid 3Immunoglobulin G 3Granulocyte Colony-Stimulating Factor 3Gemcitabine 3Disulfides 3Carmustine 3venetoclax 2tazemetostat 2sodium-iodide symporter 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma, T-Cell × belinostat × 1 year × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

NCT06561048 2026-04-08

Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Corvus Pharmaceuticals, Inc.

Phase 3 Recruiting
150 enrolled
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡